Today 3:44 AM ET (MarketWatch)
AstraZeneca (AZN.LN) is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma (MREO), The Times reported without attribution. AstraZeneca already is a partner of Mereo, and the report said it may face competition from another of the cancer and rare disease specialist’s partners, which include Novartis (NOVN.EB), OncXerna and Ultragenyx (RARE).
https://www.marketwatch.com/story/astrazeneca-weighing-bid-for-mereo-biopharma-report-2022-06-17